Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | LN-145 |
| Trade Name | |
| Synonyms | LN145 |
| Drug Descriptions |
LN145 comprises autologous tumor infiltrating lymphocytes that are isolated and expanded with IL-2, followed by infusion, potentially resulting in tumor cell death (NCI Drug Dictionary). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C135634 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Aldesleukin + Cyclophosphamide + Fludarabine + LN-145 + Pembrolizumab | Aldesleukin Cyclophosphamide Fludarabine LN-145 Pembrolizumab | 0 | 1 |
| Cyclophosphamide + Fludarabine + Interleukin-12 + LN-145 + Mesna | Cyclophosphamide Fludarabine Interleukin-12 LN-145 Mesna | 0 | 1 |
| Durvalumab + LN-145 | Durvalumab LN-145 | 0 | 1 |
| LN-145 | LN-145 | 0 | 7 |
| LN-145 + Pembrolizumab | LN-145 Pembrolizumab | 0 | 1 |